MedTrace Logo

An EQA Scheme for TPMT Activity and Thiopurine Metabolites

NCT02598908 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2017-04-25

No results posted yet for this study

Summary

Participation in EQA schemes, where available, is mandatory for the United Kingdom Accreditation Service (UKAS). No EQA scheme currently exists for TPMT and thiopurine metabolites, which is a potential shortcoming of these tests. A pilot of this project has been awarded funding by Clinical Pathology Accreditation (CPA).

The purpose of this work is to collect samples for an EQA scheme for whole blood TPMT (activity and genotype) and thiopurine metabolites, which will be run in collaboration with UK NEQAS (United Kingdom National External Quality Assessment Service), and facilitate a comprehensive world-wide service that enables laboratories providing these tests to fulfil quality goals and ultimately provide optimal patient care.

Conditions

  • External Quality Control
  • Thiopurine S-methyl Transferase (TPMT)

Interventions

DIAGNOSTIC_TEST

Quality control - enzyme activity

A blood sample will be collected from patients and staff donors, no more than twice per year.

Sponsors & Collaborators

  • Birmingham Quality

    collaborator OTHER

  • Sandwell & West Birmingham Hospitals NHS Trust

    lead OTHER

Principal Investigators

  • Jonathan Berg, FRCPath, MBA · SWBH, Pathology director

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-24
Primary Completion
2022-02-24
Completion
2022-02-24
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02598908 on ClinicalTrials.gov